APPLICATION
NDA050095
TYPE
NDA
ORIGINAL APPROVAL
1971-06-02
LATEST ACTION
2023-01-17
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued
Products
CAPASTAT SULFATE · ReferenceDiscontinued
CAPREOMYCIN SULFATE EQ 1GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE · INJECTION
Approval history
2001-10-05Manufacturing (CMC) · Supplement 43AP
1996-10-03Labeling · Supplement 41 · standardAP
1995-12-21Manufacturing (CMC) · Supplement 42AP
1988-09-12Labeling · Supplement 9AP
1987-08-12Labeling · Supplement 38AP
1987-07-08Labeling · Supplement 7AP
1987-07-08Labeling · Supplement 37AP
1987-05-26Labeling · Supplement 8AP
1987-05-26Labeling · Supplement 6AP
1987-05-26Labeling · Supplement 36AP
1987-03-06Manufacturing (CMC) · Supplement 35AP
1986-12-09Labeling · Supplement 5AP
1985-01-18Labeling · Supplement 4AP
1985-01-18Manufacturing (CMC) · Supplement 34AP
1983-09-26Labeling · Supplement 3AP
1983-09-26Manufacturing (CMC) · Supplement 33AP
1983-08-23Labeling · Supplement 2AP
1983-08-23Labeling · Supplement 32AP
1983-08-05Labeling · Supplement 1AP
1983-08-05Labeling · Supplement 31AP
1982-08-31Manufacturing (CMC) · Supplement 30AP
1982-04-12Manufacturing (CMC) · Supplement 29AP
1981-05-29Manufacturing (CMC) · Supplement 28AP
1981-03-11Labeling · Supplement 27AP
1981-03-04Manufacturing (CMC) · Supplement 26AP
1981-02-11Manufacturing (CMC) · Supplement 25AP
1980-06-03Labeling · Supplement 24AP
1980-01-25Manufacturing (CMC) · Supplement 23AP
1978-11-03Manufacturing (CMC) · Supplement 22AP
1977-09-21Manufacturing (CMC) · Supplement 21AP
1977-09-12Labeling · Supplement 20AP
1976-12-03Labeling · Supplement 19AP
1976-09-14Manufacturing (CMC) · Supplement 18AP
1975-10-28Labeling · Supplement 17AP
1975-09-23Manufacturing (CMC) · Supplement 16AP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.